GlaxoSmithKline and Access to Essential Medicines


The case summarizes GSK’s response to pressures to increase access to essential medicines in developing countries and subsequent developments.

Download options


    Upload a copy of this work     Papers currently archived: 72,856

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library


Added to PP

43 (#267,744)

6 months
1 (#386,016)

Historical graph of downloads
How can I increase my downloads?

References found in this work

No references found.

Add more references

Citations of this work

Moral Luck and Business Ethics.Christopher Michaelson - 2008 - Journal of Business Ethics 83 (4):773-787.

Add more citations

Similar books and articles

GlaxoSmithKline and Developing Country Access to Essential Medicines.N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):97-121.
Patent Funded Access to Medicines.Tom Andreassen - 2015 - Developing World Bioethics 15 (3):152-161.
Montréal Statement on the Human Right to Essential Medicines.Thomas Pogge - 2007 - Cambridge Quarterly of Healthcare Ethics 16 (1):97-108.
Supply of Medicines: Paternalism, Autonomy and Reality.D. Prayle & M. Brazier - 1998 - Journal of Medical Ethics 24 (2):93-98.
Introduction: Access to Life-Saving Medicines and Intellectual Property Rights.Doris Schroeder - 2011 - Cambridge Quarterly of Healthcare Ethics 20 (2):277-278.
Trade Rules, Intellectual Property, and the Right to Health.Lisa Forman - 2007 - Ethics and International Affairs 21 (3):337-357.
Bodies of Rights and Therapeutic Markets.João Biehl & Adriana Petryna - 2011 - Social Research: An International Quarterly 78 (2):359-386.